How long does it take for Asnib/Asiminib to take effect and evaluation of the course of treatment?

Asciminib is an oral small molecule tyrosine kinase inhibitor that specifically targets the full osteric BCR-ABL1tyrosine kinase. an> site, used for patients with chronic myelogenous leukemia (CML), especially those who are resistant or intolerant to first- or second-generation TKI such as imatinib. Its mechanism of action is by inhibiting BCR-ABL1 kinase activity, blocking leukemia cell proliferation and inducing apoptosis. Clinical data shows that improvement of some hematological or molecular indicators can generally be observed within a few weeks of taking Asciminib, but complete remission or optimal efficacy usually requires longer continuous medication.

In the early stages of treatment, patients can evaluate the effectiveness of the drug by monitoring peripheral blood and BCR-ABL1 molecular levels. Most patients can experience recovery of blood cell counts or decline in molecular indicators between 4 and 12 weeks. This stage is mainly used to initially judge drug tolerance and efficacy trends. Doctors will make necessary adjustments to the patient's dosage based on hematological reactions, liver and kidney function, and adverse reactions to ensure both efficacy and safety.

In terms of treatment evaluation, Asciminib’s clinical management emphasizes long-term and phased monitoring. Patients usually need to undergo molecular examination and evaluation when taking the medicine for 3 months, 6 months and 12 months. BCR-ABL1transcription level decreases, and whether early molecular response (EMR), complete molecular response (CMR) or other efficacy endpoints are achieved. At the same time, regular follow-up can also detect heart, liver and kidney function and hematological indicators to detect potential adverse reactions in a timely manner.

In addition, Asciminibtreatment requires individualized management. Some patients may require long-term maintenance treatment to prevent disease recurrence, and for patients with poor tolerance or adverse reactions, the regimen can be optimized through dose adjustment or intermittent medication. During the period of medication, patients should cooperate with their doctors for regular laboratory examinations and molecular monitoring, and maintain a good lifestyle, such as regular work and rest, avoiding infections, and maintaining adequate nutrition, so as to ensure the continuity of drug efficacy and medication safety.

Reference materials:https://www.drugs.com/